OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Matulonis on the Current Treatment Landscape of Recurrent Ovarian Cancers

June 20th 2022

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 19th 2022

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

June 19th 2022

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Dr. Yee on Treating Patients with Relapsed Disease in Multiple Myeloma

June 19th 2022

Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.

Dr. George on the Background of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 16th 2022

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. Llanos on Recognizing Social Determinants of Disparities in Cancer Care

June 16th 2022

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Dr. Kahn on Next Steps on Examining Racial Disparities in GI Cancer

June 15th 2022

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Dr. Raje on Current CAR T-Cell Therapies in Multiple Myeloma

June 15th 2022

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

June 15th 2022

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Sandhu on the Safety Data Seen in the MAGNITUDE Trial in Prostate Cancer

June 14th 2022

Shahneen Sandhu, MD, discusses the safety data seen in the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer

June 14th 2022

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Dr. Hamilton on the EMERALD Trial in ER-Positive/HER2-Negative Breast Cancer

June 14th 2022

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

June 13th 2022

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL

June 13th 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL

June 12th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

Dr. Mascarenhas on Updates from the MANIFEST Trial in Myelofibrosis

June 11th 2022

John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.